<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="aec1c528-a32b-4f23-b897-87e96d73aca7" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title ID="INV-88b2fd1b-0b1c-48e0-a2f5-76d85f2bb86d" mediaType="text/x-hl7-title+xml">RenAmin<sup>&#174;</sup> (Amino Acid)
        Injection<br />Pharmacy Bulk Package<br />Not for Direct Infusion</title>
<effectiveTime value="20060531" />
<setId root="aec1c528-a32b-4f23-b897-87e96d73aca7" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="2C4C9C17-81E9-7764-BDB9-9A5C3FBD4D7B" />
<effectiveTime value="20060531" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0471" codeSystem="2.16.840.1.113883.6.69" />
<name>RenAmin</name>
<formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="600">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="600" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Leucine</name>
<activeMoiety>
<activeMoiety>
<code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>leucine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="490">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="490" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="47E5O17Y3R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Phenylalanine</name>
<activeMoiety>
<activeMoiety>
<code code="47E5O17Y3R" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Phenylalanine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="450">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="450" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="K3Z4F929H6" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Lysine</name>
<activeMoiety>
<activeMoiety>
<code code="K3Z4F929H6" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Lysine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="500">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="500" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Methionine</name>
<activeMoiety>
<activeMoiety>
<code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Methionine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="500">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="500" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Isoleucine</name>
<activeMoiety>
<activeMoiety>
<code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Isoleucine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="820">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="820" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Valine</name>
<activeMoiety>
<activeMoiety>
<code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Valine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="420">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="420" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Histidine</name>
<activeMoiety>
<activeMoiety>
<code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Histidine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="380">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="380" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="2ZD004190S" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Threonine</name>
<activeMoiety>
<activeMoiety>
<code code="2ZD004190S" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Threonine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="160">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="160" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="8DUH1N11BX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Tryptophan</name>
<activeMoiety>
<activeMoiety>
<code code="8DUH1N11BX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Tryptophan</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="560">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="560" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="OF5P57N2ZX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Alanine</name>
<activeMoiety>
<activeMoiety>
<code code="OF5P57N2ZX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Alanine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="300">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="300" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="TE7660XO1C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Glycine</name>
<activeMoiety>
<activeMoiety>
<code code="TE7660XO1C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Glycine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="630">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="630" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Arginine</name>
<activeMoiety>
<activeMoiety>
<code code="94ZLA3W45F" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Arginine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="350">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="350" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="9DLQ4CIU6V" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Proline</name>
<activeMoiety>
<activeMoiety>
<code code="9DLQ4CIU6V" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Proline</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="40">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="40" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="42HK56048U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Tyrosine</name>
<activeMoiety>
<activeMoiety>
<code code="42HK56048U" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Tyrosine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="mg" value="300">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="300" />
</numerator>
<denominator unit="mL" value="100">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="100" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="452VLY9402" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Serine</name>
<activeMoiety>
<activeMoiety>
<code code="452VLY9402" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Serine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>Valine, leucine, isoleucine, methionine, phenylalanine, lysine, histidine, threonine, tryptophan, arginine, alanine, proline, glycine, serine and tyrosine</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="N762921K75" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Nitrogen</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>Glacial Acetic Acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="250">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="250" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0471-02" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS" />
</containerPackagedMedicine>
</asContent>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0471-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43172" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, GLASS" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-040f8928-4f98-4319-81a2-3d5f1512263f">
<id root="2508B452-3620-B1DE-9308-7A318DF2F42D" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DESCRIPTION SECTION" />
<title ID="INV-8467f4f7-6fd2-48d6-9d93-8097edac1a14" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text ID="INV-fed6e314-c1ab-4ae6-8eaf-b0c0cb2076e0"><paragraph ID="INV-8059dbb3-9906-4e58-bf8f-4e158b29a0cf">RenAmin<sup>&#174;</sup> (Amino
                            Acid) Injection is a sterile, nonpyrogenic, hypertonic solution of
                            essential and nonessential amino acids in a Pharmacy Bulk Package. A
                            Pharmacy Bulk Package is a container of a sterile preparation for
                            parenteral use that contains many single doses. The contents are
                            intended for use in a pharmacy admixture program and are restricted to
                            the preparation of admixtures for intravenous infusion.</paragraph><paragraph ID="INV-08cb5a72-d58d-4109-b1a1-9255d3666eb6">Each 100 mL of
                            RenAmin<sup>&#174;</sup> (Amino Acid) Injection contains:</paragraph><table frame="void"><col align="left" width="350pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">
                                        Amino Acids </td><td align="left" valign="middle"> 6.5 g</td></tr>
<tr valign="top"><td align="left" valign="middle">
                                        Total Nitrogen </td><td align="left" valign="middle"> 1 g </td></tr>
<tr valign="top"><td align="left" valign="middle"> pH (pH
                                        adjusted with glacial acetic acid) </td><td align="left" valign="middle"> 6.0 (5.0 to 7.0) </td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
<component>
<section ID="INV-0a630696-8fbb-42fc-b10d-f394f5c9aad2">
<id root="2504B3C7-5F86-2474-F510-4ABB92322232" />
<title ID="INV-24c851a9-b21c-4f80-b559-2106574dc74f" mediaType="text/x-hl7-title+xml">Essential Amino
                                Acids</title>
<text ID="INV-565c9980-c875-4b1b-a57a-0b939441a226"><table frame="void">
<col align="left" width="350pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">Valine -
                                                C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub></td><td align="left" valign="middle">820
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Leucine -
                                                C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub></td><td align="left" valign="middle">600
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Isoleucine -
                                                  C<sub>6</sub>H<sub>13</sub>NO<sub>2</sub></td><td align="left" valign="middle">500
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Methionine -
                                                  C<sub>5</sub>H<sub>11</sub>NO<sub>2</sub>S</td><td align="left" valign="middle">500
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Phenylalanine -
                                                  C<sub>9</sub>H<sub>11</sub>NO<sub>2</sub></td><td align="left" valign="middle">490
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Lysine (added as the hydrochloride salt) -
                                                  C<sub>6</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub></td><td align="left" valign="middle">450                        mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Histidine -
                                                  C<sub>6</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub></td><td align="left" valign="middle">420
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Threonine -
                                                  C<sub>4</sub>H<sub>9</sub>NO<sub>3</sub></td><td align="left" valign="middle">380
                                                mg</td></tr>
<tr valign="top"><td align="left" valign="middle">Tryptophan -
                                                  C<sub>11</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub></td><td align="left" valign="middle">160 mg</td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-0049e2d0-24a9-4ae1-a972-709deb8ae276">
<id root="FC985677-080C-C544-19CE-CBE19FFBEA07" />
<title ID="INV-130e3f56-25c2-451b-b12d-d7ad5031ea3b" mediaType="text/x-hl7-title+xml">Nonessential Amino
                                Acids</title>
<text ID="INV-b19a8b17-615d-46f7-88f7-801fa2b4b5da"><table frame="void">
<col align="left" width="350pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">Arginine &#8211;
                                                  C<sub>6</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub></td><td align="left" valign="middle">
                                                630 mg </td></tr>
<tr valign="top"><td align="left" valign="middle">Alanine &#8211;                   C<sub>3</sub>H<sub>7</sub>NO<sub>2</sub></td><td align="left" valign="middle">
                                                560 mg </td></tr>
<tr valign="top"><td align="left" valign="middle">Proline &#8211;
                                                C<sub>5</sub>H<sub>9</sub>NO<sub>2</sub></td><td align="left" valign="middle">
                                                350 mg </td></tr>
<tr valign="top"><td align="left" valign="middle">Glycine &#8211;
                                                C<sub>2</sub>H<sub>5</sub>NO<sub>2</sub></td><td align="left" valign="middle">
                                                300 mg </td></tr>
<tr valign="top"><td align="left" valign="middle">Serine &#8211;
                                                C<sub>3</sub>H<sub>7</sub>NO<sub>3</sub></td><td align="left" valign="middle">
                                                300 mg </td></tr>
<tr valign="top"><td align="left" valign="middle">Tyrosine-C<sub>9</sub>H<sub>11</sub>NO<sub>3</sub></td><td align="left" valign="middle"> 40 mg </td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-4e7e45f1-fed8-42a0-9818-76f17913be59">
<id root="9F64CAA7-8E07-5494-0C55-AB7F9678D2DB" />
<title ID="INV-e6b908b4-0c1c-485d-a524-f61e19d81891" mediaType="text/x-hl7-title+xml">Anion Profile per
                                Liter*</title>
<text ID="INV-ffd01cf6-ebd1-4b1a-ae4e-419ed29c3cc6"><table frame="void">
<col align="left" width="50pt" />
<col align="left" width="275pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle"> Acetate (1) </td><td align="left" valign="middle" /><td align="left" valign="middle"> 60                 mEq </td></tr>
<tr valign="top"><td align="left" valign="middle"> Chloride (2) </td><td align="left" valign="middle" /><td align="left" valign="middle"> 31
                                                mEq </td></tr>
<tr valign="top"><td align="left" valign="middle" /><td align="left" valign="middle">* Balanced by ions from amino acids<br /> (1)
                                                derived from pH adjustment with glacial acetic acid<br />(2) contributed by the Lysine Hydrochloride </td><td align="left" valign="middle">&#160;</td></tr>
<tr valign="top"><td align="left" colspan="2" valign="middle"> 3 mEq/L sodium bisulfite
                                                added as stabilizer </td><td align="left" valign="middle">&#160;</td></tr>
<tr valign="top"><td align="left" valign="middle"><content styleCode="bold">Osmolarity
                                                    (calc.)</content></td><td align="left" valign="middle" /><td align="left" valign="middle"> 600 mOsmol/L </td></tr>
</tbody>
</table></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-bc1c29ac-1ba2-45a8-9d82-069f8d6bdc2f">
<id root="C8FAAA96-8EA0-D095-1E94-4F11962F77A2" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title ID="INV-996a96bb-d359-4f8f-bcbe-195d1b9df27e" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text ID="INV-24bd4dce-2e37-4468-b4ee-86747e93ff46"><paragraph ID="INV-741936bd-0345-4954-8f7b-00794efd6d14">RenAmin<sup>&#174;</sup> (Amino
                            Acid) Injection provides biologically utilizable source material for
                            protein synthesis when used with appropriate calorie sources (such as
                            hypertonic dextrose or fat emulsion), electrolytes, vitamins and
                            minerals.</paragraph><paragraph ID="INV-fd1ce853-2536-42d5-9e11-ac59b411f237">As a concentrated
                            source of essential amino acids, RenAmin<sup>&#174;</sup> (Amino Acid) Injection provides
                            maximal protein intake with low volume administration. The essential
                            amino acids are included as approximately 60% w/w of total amino acids.
                            Each 250 mL unit of this injection meets or exceeds the recommended
                            daily intake of essential amino acids. Nonessential amino acids have
                            been included to meet requirements established in investigations of
                            acute and chronic renal failure patients fed parenterally. The 40% w/w
                            of nonessential amino acids includes histidine (considered an essential
                            amino acid in renal failure), arginine, and other nonessential amino
                            acids as additional sources of nitrogen that have been shown to enhance
                            nitrogen balance and weight gain.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-0cd1ea03-5eb2-425e-845d-e0626f538b46">
<id root="0C7500BF-EC38-B237-D2C1-D7488BD92DEB" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="INDICATIONS AND USAGE SECTION" />
<title ID="INV-bbba82d5-49c6-461c-88c1-9cb9bfa72f2c" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text ID="INV-0179d173-fe28-48cf-894f-7aea5d35d344"><paragraph ID="INV-e4525132-c728-4706-bd72-bdfb680b03fc">RenAmin<sup>&#174;</sup> (Amino
                            Acid) Injection is indicated as an adjunct in the offsetting of nitrogen
                            loss or in the treatment of negative nitrogen balance in potentially
                            reversible renal decompensation when the alimentary tract cannot or
                            should not be used; gastrointestinal absorption of protein is impaired;
                            or metabolic requirements for protein are substantially increased, as
                            with extensive burns.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-c16cab34-0d62-42eb-b687-f958d8ed757a">
<id root="1D6CB796-378C-4F1D-303F-18FB944D6ECC" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CONTRAINDICATIONS SECTION" />
<title ID="INV-91d7c2cf-c341-4dc1-934b-ac679824d5cd" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text ID="INV-44bc0ac0-2ae2-459b-8103-9a6410b2d2c5"><paragraph ID="INV-fc48edb2-d579-4716-899d-85c85c8e84f9">Severe uncorrected
                            electrolyte and acid base imbalance</paragraph><paragraph ID="INV-9c7d2b6b-a3e3-4a4b-aae6-b2d7682b9752">Severe liver
                            disease or hepatic coma</paragraph><paragraph ID="INV-5efabf32-16a2-4634-bbd2-4726e8e5c818">Hyperammonemia</paragraph><paragraph ID="INV-123e0de7-7263-4493-8d5a-ebd1d29167a5">Hypersensitivity to
                            one or more amino acids</paragraph><paragraph ID="INV-a75c0ac7-921f-46b6-830b-60cdee46eedd">Decreased
                            circulating blood volume</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-09000754-43ca-4b0c-9180-c6707ab24b8e">
<id root="6D41BA14-B43A-F9D5-EEA4-027DC91E2E07" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="WARNINGS SECTION" />
<title ID="INV-34329ab5-ad55-479b-a98b-8ef0c8573a62" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text ID="INV-b0792636-991d-4988-9edd-ac75237fa79f"><paragraph ID="INV-1848cce9-ac0e-4d1e-9a7f-509cc4aebd18"><content styleCode="bold">This injection is for compounding only, not
                                for direct infusion.</content></paragraph><paragraph ID="INV-cd4a79f6-e59f-401e-8389-580528cda997">Proper
                            administration of RenAmin<sup>&#174;</sup> (Amino Acid) Injection requires a knowledge
                            of fluid and electrolyte balance and nutrition as well as clinical
                            expertise in recognition and treatment of the complications which may
                            occur.</paragraph><paragraph ID="INV-187371fa-56c4-498d-a419-072746980e8d">Administration of
                            amino acid solutions to a patient with hepatic insufficiency may result
                            in serum amino acid imbalances, hyperammonemia, stupor and coma.</paragraph><paragraph ID="INV-1db143a5-4266-4686-9bf1-4bef3a15c123">Hyperammonemia is
                            of <content styleCode="bold">special significance in infants.</content>
                            This reaction appears to be related to a deficiency of the urea cycle
                            amino acids of genetic or product origin. It is essential that blood
                            ammonia be measured frequently in infants.</paragraph><paragraph ID="INV-a33e4d05-0253-4666-9fe4-95aefa4ec827">This injection has
                            no added electrolytes. Clinically significant hypocalcemia,
                            hypophosphatemia or hypomagnesemia may occur. Electrolyte replacement
                            may become necessary.</paragraph><paragraph ID="INV-fa46695c-0282-462e-baab-8865dbbc59e3">Contains sodium
                            bisulfite, a sulfite that may cause allergic-type reactions including
                            anaphylactic symptoms and life-threatening or less severe asthmatic
                            episodes in certain susceptible people. The overall prevalence of
                            sulfite sensitivity in the general population is unknown and probably
                            low. Sulfite sensitivity is seen more frequently in asthmatic than in
                            nonasthmatic people.</paragraph><paragraph ID="INV-61aabe87-f546-4d0f-a1ff-771439b91d95">This injection
                            should not be administered simultaneously with blood through the same
                            infusion set because of the possibility of pseudoagglutination.</paragraph><paragraph ID="INV-df700e3d-d1c8-4811-b622-40eae578fc36">RenAmin<sup>&#174;</sup> (Amino
                            Acid) Injection does not replace dialysis and conventional supportive
                            therapy in patients with renal failure.</paragraph><paragraph ID="INV-083f35da-9036-483b-86f1-832a4b89a20b">WARNING: This
                            product contains aluminum that may be toxic. Aluminum may reach toxic
                            levels with prolonged parenteral administration if kidney function is
                            impaired. Premature neonates are particularly at risk because their
                            kidneys are immature, and they require large amounts of calcium and
                            phosphate solutions, which contain aluminum.</paragraph><paragraph ID="INV-303d0eae-bf1b-4982-a788-23794a8ced78">Research indicatesthat patients with impaired kidney function, including premature
                            neonates, who receive parenteral levels of aluminum at greater than 4 to
                            5 &#956;g/kg/day accumulate aluminum at levels associated with central
                            nervous system and bone toxicity. Tissue loading may occur at even lower
                            rates of administration.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-543e05aa-1d74-49a5-8138-66dd1d3722e6">
<id root="34C11E1F-93EC-29AA-A1DD-53617667E427" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PRECAUTIONS SECTION" />
<title ID="INV-5346bdf8-adfe-4782-bea5-e3ccf11abf91" mediaType="text/x-hl7-title+xml">PRECAUTIONS</title>
<text ID="INV-19ff8fdc-bee6-41a4-abc8-4134753e2b70"><paragraph ID="INV-9d616dbd-c1cb-4f6e-8d65-a3fc3bf36582">It is essential to
                            provide adequate calories concurrently if parenterally administered
                            amino acids are to be retained by the body and utilized for protein
                            synthesis. Concentrated dextrose solutions are an effective source of
                            such calories.</paragraph><paragraph ID="INV-578675c6-41df-426f-9379-dc9c295bab75">With the
                            administration of RenAmin<sup>&#174;</sup> (Amino Acid) Injection in combination with
                            highly concentrated dextrose solutions, hyperglycemia, glycosuria and
                            hyperosmolar syndrome may result. Blood and urine glucose should be
                            monitored on a routine basis in patients receiving this therapy.</paragraph><paragraph ID="INV-2d936a03-7d59-4da4-ad7a-1603af1ecbf2">Sudden cessation in
                            administration of a concentrated dextrose solution may result in insulin
                            reaction due to continued endogenous insulin production. Parenteral
                            nutrition mixtures should be withdrawn slowly.</paragraph><paragraph ID="INV-7a3b71ec-d4b3-4d7d-b030-befc8bb478cc">Electrolytes may be
                            added to RenAmin<sup>&#174;</sup> (Amino Acid) Injection as dictated by the patient's
                            electrolyte profile.</paragraph><paragraph ID="INV-6346b196-2e99-4a2e-8383-871ff18dc5a1">Strongly hypertonic
                            nutrient solutions should be administered through an indwelling
                            intravenous catheter with the tip located in the superior vena cava.</paragraph><paragraph ID="INV-a8b33dd8-cfd9-49e0-bbce-f2670f92467d">Care should be
                            taken to avoid excess fluid accumulation, particularly in patients with
                            renal disease, pulmonary insufficiency and heart disease.</paragraph><paragraph ID="INV-e0276cab-9515-4c4f-bcd6-4c1455169f57">During amino acid
                            administration in the absence of supporting carbohydrate metabolism, an
                            accumulation of ketone bodies in the blood often occurs. Correction of
                            ketonemia usually can be accomplished by administering some
                            carbohydrates.</paragraph><paragraph ID="INV-c52776c0-8f63-4d9d-aac5-e58f47fd5aaa">Drug product
                            contains no more than 25 &#956;g/L of aluminum.</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section ID="INV-bf063641-c9cb-4e1e-88c5-48ad4dac9c42">
<id root="45DC4D94-1093-847C-1BC7-6E8E57AF4824" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="LABORATORY TESTS SECTION" />
<title ID="INV-26f5a23c-d8b9-4193-a71d-e731259c4744" mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text ID="INV-cf02f0b1-93e6-4c34-95b9-1929430c6d12"><paragraph ID="INV-f6f11364-9dca-4387-b3b6-87995cf30aa6"><content styleCode="bold">Frequent clinical evaluation and   laboratory determinations are necessary for proper                       monitoring during administration.</content></paragraph><paragraph ID="INV-2df6f59a-696b-4ee5-a8e4-7d02271843cc">Studies
                                    should include blood urea nitrogen, blood sugar, serum proteins,
                                    kidney and liver function tests, electrolytes, acid-base
                                    balance, hemogram, carbon dioxide combining power or content,
                                    serum osmolarities, blood cultures and blood ammonia levels.
                                    Circulating blood volume should be determined, if
                                indicated.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-e710c2ad-4f3e-402f-9e28-7e81f2c00309">
<id root="232C0284-3A04-EF20-AF39-EEF5D2E35917" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION" />
<title ID="INV-8ebc1d66-9040-474c-8fe5-aeba1f188c36" mediaType="text/x-hl7-title+xml">Carcinogenesis,
                                Mutagenesis, Impairment of Fertility:</title>
<text ID="INV-72b1ff23-213b-4597-89f5-26ea6c6c606b"><paragraph ID="INV-3f4f5cbb-cccf-4396-bf1f-339bf6ffc771">Studies
                                    with RenAmin<sup>&#174;</sup> (Amino Acid) Injection have not been performed to
                                    evaluate carcinogenesis potential, mutagenic potential, or
                                    effects on fertility.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-7094b296-5039-468d-9183-f48e9c8f7896">
<id root="04C6D423-F9F5-EE68-2E29-DA1D76565BA2" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-09e2b523-b359-4960-adfd-105bd595b68d" mediaType="text/x-hl7-title+xml">Pregnancy:</title>
<effectiveTime value="20060531" />
<component>
<section ID="INV-ed86f8a1-a5ef-4946-b4d5-57e491472e10">
<id root="8213E92F-920E-E658-0736-6BF5DC82E353" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-de027059-5797-4bf0-8c72-b191562785e5" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects</title>
<effectiveTime value="20060531" />
<component>
<section>
<id root="1E1516CC-B5EA-1C50-FC49-1EF736156824" />
<title ID="INV-0909be67-be9a-41b7-a55d-d85590d0e6d0" mediaType="text/x-hl7-title+xml">Pregnancy Category C.</title>
<text ID="INV-95389233-3963-4700-9619-455bd80aaf64"><paragraph ID="INV-b4c7426c-24ae-4100-ab38-fef91774e415">Animal reproduction studies have not been
                                                    conducted with RenAmin<sup>&#174;</sup> (Amino Acid) Injection.
                                                    It is also not known whether RenAmin<sup>&#174;</sup> (Amino
                                                  Acid) Injection can cause fetal harm when
                                                  administered to a pregnant woman or can affect
                                                    reproduction capacity. RenAmin<sup>&#174;</sup> (Amino Acid)
                                                  Injection should be given to a pregnant woman
                                                  only if clearly needed.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-1d1174ca-9688-4919-939b-e987fda19823">
<id root="104B52F6-6AF9-EA84-7CA2-3EEA475B6C59" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="NURSING MOTHERS SECTION" />
<title ID="INV-b33e2848-230d-44ce-92c7-8d7c7563fd4c" mediaType="text/x-hl7-title+xml">Nursing Mothers:</title>
<text ID="INV-88a47d9d-e951-4dc0-99db-d9a30554ff5d"><paragraph ID="INV-75819d8f-7e49-4718-a371-77f92d7c307a">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, and because of the potential
                                    for adverse reactions, e.g., hyperammonemia in nursing infants,
                                    caution should be exercised when RenAmin<sup>&#174;</sup> (Amino Acid) Injection
                                    is administered to a nursing mother.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-42d8f922-cc5c-4c9d-b37d-c682d742a466">
<id root="AA7DA1CF-20AD-E8C9-5B4D-1196FE41D502" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PEDIATRIC USE SECTION" />
<title ID="INV-655133ec-315c-42d3-82df-1ff301767bbb" mediaType="text/x-hl7-title+xml">Pediatric Use:</title>
<text ID="INV-e3a7c867-ebfb-4dd0-ac3b-7a74c81d6d1a"><paragraph ID="INV-7cfa2169-af14-491d-bc76-c1df1c3be4e6">Safety and
                                    effectiveness of RenAmin<sup>&#174;</sup> (Amino Acid) Injection have not been
                                    established by adequate and well-controlled studies in pediatric                            patients.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-c2c7ec64-0e0e-4c53-8c94-94d88fd964f7">
<id root="5F17B20E-B30F-4739-8237-7A3F404B5E4D" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="GERIATRIC USE SECTION" />
<title ID="INV-992001b7-cc3b-422a-8ab3-6f958c3aed8d" mediaType="text/x-hl7-title+xml">Geriatric Use:</title>
<text ID="INV-45fcd871-f398-414b-b05a-d0e116cf4341"><paragraph ID="INV-b15bef63-3529-4fa3-b865-df667add9791">Clinical
                                    studies of RenAmin<sup>&#174;</sup> (Amino Acid) Injection did not include
                                    sufficient numbers of subjects aged 65 and over to determine
                                    whether they respond differently from other younger subjects.
                                    Other reported clinical experience has not identified
                                    differences in responses between the elderly and younger
                                    patients. In general, dose selection for an elderly patient
                                    should be cautious, usually starting at the low end of the
                                    dosing range, reflecting the greater frequency of decreased
                                    hepatic, renal, or cardiac function, and of concomitant disease
                                    or drug therapy.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-bbeed8d2-c8a8-4196-b15e-eba0abfe3189">
<id root="C4DA92E0-C0F6-43C6-4FF2-3B094CCF179D" />
<title ID="INV-413f3cdb-0af1-4d82-bf4c-5bb4a8cc9bda" mediaType="text/x-hl7-title+xml">SPECIAL PRECAUTIONS</title>
<text ID="INV-439570f8-1fe5-40f3-bdfc-82c71b889a1f"><paragraph ID="INV-acfea70a-c29a-4bb7-a454-8b8338ae7749">Administration of
                            amino acid solutions and other nutrients via central or peripheral
                            venous catheter may be associated with complications which can be
                            prevented or minimized by careful attention to all aspects of the
                            procedure. This includes attention to solution preparation,
                            administration and patient monitoring. <content styleCode="bold">It is
                                essential that a carefully prepared protocol, based on current
                                medical practices, be followed, preferably by an experienced
                            team.</content></paragraph><paragraph ID="INV-168b543a-7f32-49b0-b34b-eabcda00a837">Although a detailed
                            discussion of the complications is beyond the scope of this insert, the
                            following summary lists those based on current literature:</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section ID="INV-3f958667-d9d9-4f50-a180-f3d789ba7707">
<id root="05187F74-B702-8AE0-C41C-9B7575AB44D5" />
<title ID="INV-6da65b4f-1a15-4bed-a342-0dc77f2574be" mediaType="text/x-hl7-title+xml">Technical:</title>
<text ID="INV-26514432-5986-4cb2-82cb-fbf96eef9fd4"><paragraph ID="INV-6ec69455-09c2-4a34-bbfd-fa3d76711a3c">The
                                    placement of a central venous catheter should be regarded as a
                                    surgical procedure. The physician should be fully acquainted
                                    with various techniques of catheter insertion as well as
                                    recognition and treatment of complications. For details of
                                    techniques and placement sites consult the medical literature.                X-ray is the best means of verifying catheter placement.
                                    Complications known to occur from the placement of central
                                    venous catheters are pneumothorax, hemothorax, hydrothorax,
                                    artery puncture and transection, injury to the brachial plexus,
                                    malposition of the catheter, formulation of arteriovenous
                                    fistula, phlebitis, thrombosis, cardiac arrhythmia and catheter                     embolus.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-e0b8c3c9-23ba-4d48-824e-2086694fa04e">
<id root="B3C4D94A-626C-F6E4-1678-E36B86C213BB" />
<title ID="INV-28ebe4e7-88cb-45e1-850b-91e9a27a4662" mediaType="text/x-hl7-title+xml">Septic:</title>
<text ID="INV-63d6336c-c684-4746-8581-5b5dfb7be159"><paragraph ID="INV-8b951adc-88a3-44c5-96a7-e8e992715621">The
                                    constant risk of sepsis is present during administration of
                                    parenteral nutrition solution. Since contaminated solutions and
                                    infusion catheters are potential sources of infection, it is
                                    imperative that the preparation of the solution and the
                                    placement and care of catheters be accomplished under controlled
                                    aseptic conditions. If fever develops, the solution, its
                                    delivery system and the site of the indwelling catheter should
                                    be changed.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-b6fe01ae-093d-4c2f-96b4-6c043805f8cc">
<id root="6D621917-CEF4-8E96-1858-7805BADAD88F" />
<title ID="INV-57da910a-131e-4f54-8d4a-662729dc4670" mediaType="text/x-hl7-title+xml">Metabolic:</title>
<text ID="INV-5884d158-7fc3-4c5f-860a-47b325a83855"><paragraph ID="INV-8afbd69c-4320-4f11-b069-2ee390e07c7f">The
                                    following metabolic complications have been reported: metabolic
                                    acidosis, hypophosphatemia, alkalosis, hyperglycemia and
                                    glycosuria, osmotic diuresis and dehydration, rebound
                                    hypoglycemia, elevated liver enzymes, hypo- and                 hypervitaminosis, electrolyte imbalances and hyperammonemia.
                                    Frequent clinical evaluation and laboratory determinations are
                                    necessary, especially during the first few days of therapy, to
                                    prevent or minimize these complications.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-5cec6c96-b5cc-4d46-984b-da989d542d1a">
<id root="86A7AC8B-46AB-C533-0190-43EAAA66FD40" />
<title ID="INV-0b8adfb2-5fac-4d47-92e7-500427aebf21" mediaType="text/x-hl7-title+xml">Special Precautions
                                in Patients with Renal Insufficiency</title>
<text ID="INV-9755d28e-d78d-4315-8d48-0e91d790d42d"><paragraph ID="INV-6a63bf81-abb1-4ee4-a626-7b0f75baade8">Frequent
                                    laboratory studies are necessary in patients with renal
                                    insufficiency. In renal failure, hyperglycemia may not be
                                    reflected by glycosuria. Blood glucose must be determined
                                    frequently, often every six hours to guide dosage of dextrose,
                                    and insulin should be given, if required.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-b36c7f3e-f153-4914-beb7-37d67ec0051d">
<id root="CF08A719-8163-C486-01E2-F3101373DD89" />
<title ID="INV-fd63c803-09bf-49be-bdaf-28be02604aa8" mediaType="text/x-hl7-title+xml">Special Precautions
                                in Pediatric Patients</title>
<text ID="INV-0a11e8f7-549f-44ee-8eb9-1e4abce961ba"><paragraph ID="INV-2960e0ef-37d8-4406-bd29-6c69e29f8f30">RenAmin<sup>&#174;</sup>
                                    (Amino Acid) Injection should be used with special caution in
                                    pediatric patients with acute renal failure, especially low
                                    birth weight infants. Laboratory and clinical monitoring of
                                    pediatric patients, especially those who are nutritionally
                                    depleted, must be extensive and frequent. See <linkHtml ID="INV-be8e9071-5138-4d29-abe7-87c06c761211" href="#INV-1707e372-4727-441d-a643-f8c2b4609a30">Children</linkHtml> section under <linkHtml ID="INV-9f09f4f9-98f0-43d7-a9d9-e500d674fdc5" href="#INV-06209a73-5e0e-4da4-8e67-5fa07d832830">DOSAGE AND
                                        ADMINISTRATION</linkHtml> for additional information.
                                    Frequent monitoring of blood glucose is required in low birth
                                    weight or septic infants, as hypertonic dextrose infusion
                                    involves a greater risk of hyperglycemia in such
                                patients.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-bfe71b27-0a15-47c9-b0ff-18751fc1ddd9">
<id root="B0D10F87-5684-8204-C5EC-8682D90EDBD3" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="ADVERSE REACTIONS SECTION" />
<title ID="INV-2a559897-dee7-4c82-b2cb-4213a06c9d6b" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text ID="INV-32233369-c3e3-4363-9743-f8cad6c9abac"><paragraph ID="INV-80689840-94fc-4b8f-98de-cb8431e8a5ba">See <linkHtml ID="INV-0d17afaf-92ac-43ec-809a-05c98cd57a6a" href="#INV-1848cce9-ac0e-4d1e-9a7f-509cc4aebd18">WARNINGS</linkHtml>
                            and <linkHtml ID="INV-98903f95-7d1b-498f-a5aa-cdde4637dc7c" href="#INV-9d616dbd-c1cb-4f6e-8d65-a3fc3bf36582">PRECAUTIONS</linkHtml></paragraph><paragraph ID="INV-71cafa57-06ae-438b-b4c4-8e86332abaef">Adverse effects
                            include metabolic, electrolyte, acid-base and fluid imbalances unless
                            special care with monitoring and corrective management is maintained
                            during RenAmin<sup>&#174;</sup> (Amino Acid) injection administration.</paragraph><paragraph ID="INV-4d21b245-60eb-4b8e-840e-3d00ace1f932">Infusion of any
                            hypertonic solution can result in local inflammatory reactions. Policies
                            and procedures should be established for the recognition and management
                            of such reactions.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-8a753c4e-62c2-46cb-91b2-4b537958e926">
<id root="1BE87C82-586F-5E8C-A318-37E2A128A179" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title ID="INV-6db96a59-e982-4c96-be0b-022a9054e167" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text ID="INV-38f55389-66be-4077-af38-6bcfbec0c4e3"><paragraph ID="INV-06209a73-5e0e-4da4-8e67-5fa07d832830">If a patient is                        unable to take oral nourishment for a prolonged period of time,             institution of total parenteral nutrition (TPN) with exogenous calories
                            should be considered.</paragraph><paragraph ID="INV-3ea485db-42f0-4c61-97d4-9d5ae45fe98f">Fat emulsion
                            coadministration should be considered when prolonged (more than 5 days)
                            parenteral nutrition is required in order to prevent essential fatty
                            acid deficiency (EFAD). Serum lipids should be monitored for evidence of
                            EFAD in patients maintained on fat free TPN.</paragraph></text>
<effectiveTime value="20060531" />
<component>
<section ID="INV-e25c61ef-e432-4dea-819b-1a99fc37e642">
<id root="70FCF3AE-26A3-D05F-479B-C5B8EC74446B" />
<title ID="INV-e8547e21-3451-428c-8440-aafa2152e94d" mediaType="text/x-hl7-title+xml">Adult:</title>
<text ID="INV-47971471-17ea-4c70-9348-1a663fe82d74"><paragraph ID="INV-0f3e4fec-ca59-4eaa-8d5f-0720b10b183a">The total
                                    daily dose of RenAmin<sup>&#174;</sup> (Amino Acid) Injection depends on the
                                    patient's metabolic requirement and clinical response. The
                                    determination of nitrogen balance and accurate daily body
                                    weights, corrected for fluid balance, are probably the best
                                    means of assessing individual nitrogen requirements.</paragraph><paragraph ID="INV-4609700c-1f22-47ca-9fa7-329bacfc7157">Nutritional
                                    management of renal decompensation includes providing sufficient
                                    amino acid and caloric support for protein synthesis while not                            exceeding renal capacity for excretion of metabolic wastes. A
                                    dosage of 2.5 to 5.0 grams of nitrogen per day with adequate           calories will maintain nitrogen equilibrium in most patients
                                    with uremia. If more nitrogen and calories are required, higher
                                    dosages may be administered, provided great care is taken to
                                    avoid exceeding limits of fluid intake or glucose tolerance.</paragraph><paragraph ID="INV-b7286101-3eb5-4b97-bbf7-7abf2c3a00cf">Dosage
                                    should be guided by fluid, glucose and nitrogen tolerances, as
                                    well as metabolic and clinical responses. The rate of increase
                                    in blood urea nitrogen concentration generally diminishes when
                                    infusion of amino acids is accompanied by adequate calories.
                                    However, excessive intake of protein or increased protein
                                    catabolism may alter this response.</paragraph><paragraph ID="INV-ddeba8a1-1d75-43b6-9008-dfb3e14b0c61">The usual
                                    daily dose ranges from 250 to 500 mL of RenAmin<sup>&#174;</sup> (Amino Acid)
                                    Injection equivalent to 2.5 to 5.0 grams of nitrogen in 16.2 to
                                    32.5 grams of amino acids.</paragraph><paragraph ID="INV-4841200e-0a91-4316-b522-071a88d350a1">Adequate
                                    calories should be administered simultaneously.</paragraph><paragraph ID="INV-1bac61d4-b766-4bcf-ab00-21efff0c436f">Patients
                                    receiving RenAmin<sup>&#174;</sup> (Amino Acid) Injection should be monitored
                                    carefully and their electrolyte requirements individualized.
                                    Electrolyte supplementation may be required. This injection
                                    contains approximately 60 mEq acetate and 31 mEq chloride.</paragraph><paragraph ID="INV-399c3f8a-3f9b-4c68-9d8e-1125042142c0">Electrolyte
                                    (phosphorous, potassium and magnesium) concentrations usually
                                    fall during administration of RenAmin<sup>&#174;</sup> (Amino Acid) Injection.
                                    Particular care should be taken in the presence of cardiac
                                    arrhythmias or digitalis toxicity to assure that these
                                    electrolytes are supplemented when necessary.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-680090a1-9626-430c-9c47-a4fef273842b">
<id root="05F08032-FE53-8534-43B1-6EAFF85C7F50" />
<title ID="INV-6f5be7f9-e9eb-4333-916f-f5ff15ddbd3c" mediaType="text/x-hl7-title+xml">Children:</title>
<text ID="INV-4595152b-1681-4627-827a-80876ede6668"><paragraph ID="INV-1707e372-4727-441d-a643-f8c2b4609a30">Pediatric
                                    requirements vary depending upon growth, nutritional state and
                                    degree of renal insufficiency. A dosage of 0.5 to 1.0 gram of
                                    amino acids per kilogram body weight per day will meet the
                                    requirements of the majority of pediatric patients. Initial
                                    daily dosage should be low and increased slowly. More than one
                                    gram of essential amino acids per kilogram of body weight per
                                    day is not recommended. The total volume of nutritional
                                    solution, and the rate at which it is administered, will vary
                                    with the child&#8217;s age, nutritional and growth state, as well as
                                    the degree of renal failure. See <linkHtml ID="INV-73a2287e-0a22-4812-a8c3-eb5f35de6a1d" href="#INV-2960e0ef-37d8-4406-bd29-6c69e29f8f30">Special
                                        Precautions in Pediatric Patients</linkHtml> for additional
                                    information.</paragraph><paragraph ID="INV-6e9832c3-6f62-467f-87f3-91a37db1f9ce">Maintenance
                                    vitamins, additional electrolytes and trace elements should be
                                    administered as required.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-28cf153b-da7b-477b-ae27-8b1320bb613f">
<id root="BB787E40-D2FB-71F5-9BC7-833D83CBEF54" />
<title ID="INV-4cdae8c8-33f8-4e58-8ffd-cf355c3d970f" mediaType="text/x-hl7-title+xml">Central Vein
                                Administration:</title>
<text ID="INV-d9b15ce2-f114-4710-ac92-b684cb12a94e"><paragraph ID="INV-2ecf15aa-1565-4577-b6cd-dbd32e658a6c">Hypertonic
                                    mixtures of amino acids and dextrose may be administered safely
                                    by continuous infusion through a central vein catheter with the
                                    tip located in the vena cava. In addition to meeting nitrogen
                                    needs, the administration rate is governed, especially during
                                    the first few days of therapy, by the patient's tolerance to
                                    dextrose. Daily intake of amino acids and dextrose should be
                                    increased gradually to the maximum required dose as indicated by
                                    frequent determinations of urine and blood sugar levels.</paragraph><paragraph ID="INV-bc6d5cf3-4134-49d5-bb12-b84996bae69d">Uremic
                                    patients frequently are glucose intolerant. Provision of            adequate calories in the form of hypertonic dextrose may require
                                    the administration of exogenous insulin to prevent hyperglycemia
                                    and glycosuria.</paragraph><paragraph ID="INV-bc7f0436-93d3-472b-b19e-614a7c57b624">Parenteral
                                    nutrition may be started at lower administration rates and with
                                    infusates containing lower concentrations of dextrose; dextrose
                                    content and rate may be gradually increased to estimated caloric
                                    needs as the patient&#8217;s glucose tolerance increases. The
                                    patient&#8217;s fluid, nitrogen and glucose tolerance should be the
                                    determining factor of the rate of administration.</paragraph><paragraph ID="INV-9acb5f11-931c-471d-9c10-b3a0c70ad016">Sudden
                                    cessation in administration of concentrated dextrose solutions
                                    may result in insulin reactions due to continued endogenous
                                    insulin production. Such solutions should be withdrawn
                                slowly.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-96330136-1257-43a7-aaf9-d43f243cec66">
<id root="F7957481-2E92-8E8C-F22B-8C61CE6D1572" />
<title ID="INV-bbcbe9a5-b04c-4547-a0b9-c17275f9ed4b" mediaType="text/x-hl7-title+xml">Peripheral Vein
                                Administration:</title>
<text ID="INV-c4a0b4e4-d149-44ef-8654-141552ed72e4"><paragraph ID="INV-81df64ca-4446-4090-8763-1d9e5b0dba86">For
                                    patients requiring parenteral nutrition in whom the central vein
                                    route is not indicated, this injection can be mixed with low
                                    concentration dextrose solutions and administered by peripheral
                                    vein with fat emulsions.</paragraph><paragraph ID="INV-7b096ccb-c9c9-4689-b073-b869143a66fe">Intravenous
                                    fat emulsions provide approximately 1.1 kcal/mL (10%) or 2.0
                                    kcal/mL (20%) and may be administered along with amino
                                    acid-dextrose solutions through a short Y-connector near the
                                    infusion site to supplement caloric intake. Fat, however, should
                                    not be the sole caloric intake since studies have indicated that
                                    glucose is more nitrogen sparing in the stressed patient.</paragraph><paragraph ID="INV-43723e3d-f77d-41bb-aafe-208014da6271">Parenteral                                    drug products should be inspected visually for particulate
                                    matter and discoloration prior to administration whenever
                                    solution and container permit. Use of a final filter is
                                    recommended during administration of all parenteral solutions
                                    where possible.</paragraph><paragraph ID="INV-fd3e552a-b68d-4b71-99aa-ad6817c307b0"><content styleCode="underline bold">Do not use unless solution
                                        is clear and vacuum is present. Unit must be used with a
                                        vented set or a nonvented set with a vented spike
                                    adapter.</content></paragraph><paragraph ID="INV-3d7c6954-cebf-4c0e-9084-ce4ef0a1593e">RenAmin<sup>&#174;</sup>
                                    (Amino Acid) Injection in the Pharmacy Bulk Package is intended
                                    for use in the preparation of sterile, intravenous admixtures.
                                    Additives may be incompatible with the fluid withdrawn from this
                                    container. Complete information is not available. Those
                                    additives known to be incompatible should not be used. Consult
                                    with pharmacist, if available. When compounding admixtures, use
                                    aseptic technique. Mix thoroughly. Do not store any unused
                                    portion of RenAmin&#174; (Amino Acid) Injection.</paragraph><paragraph ID="INV-8429d2fd-55ea-4bb0-b389-57ba9b98cfe0">Solutions
                                    should be used promptly after mixing. Any storage should be
                                    under refrigeration and limited to a brief period of time,
                                    preferably less than 24 hours.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-794bfee6-894c-4b02-8137-4e2c8c2f6637">
<id root="66926D6F-5C4D-1B70-5ADB-9CCF59B8DEEA" />
<title ID="INV-29f95a6e-a327-459d-9a98-1176a7633a8b" mediaType="text/x-hl7-title+xml">DIRECTIONS FOR USE OF THE
                        PHARMACY BULK PACKAGE CONTAINER</title>
<text ID="INV-1399fe04-6cd5-4ab7-a942-95d828c9a3eb"><paragraph ID="INV-03dad8be-d47d-43ea-a9ab-ea327466b230">For compounding
                            only, not for direct infusion.</paragraph><paragraph ID="INV-2dc2ccef-043c-4551-bf64-5aaf4e743ecd">1. The Pharmacy
                            Bulk Package is to be used only in a suitable work area such as a
                            laminar flow hood (or an equivalent clean air compounding area).</paragraph><paragraph ID="INV-56c49572-f380-4b01-b854-5008bb330f71">2. Remove outer
                            seal and metal disc.</paragraph><paragraph ID="INV-47c03140-a3d8-41fc-997e-754941d6392b">3. Swab surface of
                            stopper using approved technique.</paragraph><paragraph ID="INV-db18a83b-9466-40f6-a453-d7dc78bd9e65">4. Insert vented
                            connector of solution transfer set and suspend unit. Refer to directions
                            accompanying set.</paragraph><paragraph ID="INV-c04e5b7a-0b5e-4fd1-822c-e660f85c7b1e">Note: The closure
                            shall be penetrated only one time with a suitable sterile transfer
                            device or dispensing set which allows measured dispensing of the
                            contents.</paragraph><paragraph ID="INV-9d4e90a8-d916-4bab-9e01-c35c983a023c">5. Once container
                            closure has been penetrated, withdrawal of contents should be completed
                            without delay. After initial entry, maintain contents at room
                            temperature (25&#186;C/77&#186;F) and dispense within 4 hours.</paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
<component>
<section ID="INV-e284bf8a-1f91-4ab2-83db-5f29918fcc15">
<id root="6924CCAC-89F3-BEE1-9F89-7FD5AFFBF44F" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HOW SUPPLIED SECTION" />
<title ID="INV-8630eb02-58e6-482a-a75e-48f06ecfc070" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text ID="INV-1c65fc14-da41-494b-92ec-1f0b06fcf2e8"><paragraph ID="INV-7677f7f5-47cb-4fea-81f4-34762e848353">RenAmin<sup>&#174;</sup> (Amino
                            Acid) Injection is available in glass Pharmacy Bulk Packages as follows:</paragraph><table frame="void"><col align="left" width="100pt" />
<col align="left" width="100pt" />
<col align="left" width="150pt" />
<tbody valign="top">
<tr valign="top"><td align="left" valign="middle">2A6222</td><td align="left" valign="middle">250
                                        mL</td><td align="left" valign="middle">NDC
                                        0338-0471-02</td></tr>
<tr valign="top"><td align="left" valign="middle">2A6223</td><td align="left" valign="middle">500 mL</td><td align="left" valign="middle">NDC 0338-0471-03</td></tr>
</tbody>
</table><paragraph ID="INV-caa4d72d-3b3c-40c3-b550-d91ce5d96f07">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. Protect from freezing. It is recommended the product be stored at
                            room temperature (25&#186;C/77&#186;F): brief exposure up to 40&#186;C does not
                            adversely affect the product, Protect from light until immediately prior         to use.</paragraph><paragraph ID="INV-58a88b5b-d6c0-4436-94a5-c856ea605cc1">*For Bar Code
                            Position Only</paragraph><paragraph ID="INV-6bd5771d-1045-4674-bbd9-72eb121e2398">071941631</paragraph><paragraph ID="INV-ffc89a07-91f7-48f9-9610-b2c3c88fc6eb"><content styleCode="bold">Baxter Healthcare Corporation</content></paragraph><paragraph ID="INV-b86788fc-e216-49e7-9396-741e3bb82434">Clintec Nutrition
                            Division</paragraph><paragraph ID="INV-ce3be102-7c70-4421-9d37-e97701270238">Deerfield, IL,
                            60015 USA</paragraph><paragraph ID="INV-36d0e80d-22a6-4e58-a528-0ac6fc5c3ca3">Printed in USA</paragraph><paragraph ID="INV-12bb098d-e274-4b96-b2ea-d3f911a069db">&#169;Copyright 1997,
                            2000, Baxter Healthcare Corporation. All rights reserved.</paragraph><paragraph ID="INV-5713761c-4b92-4caf-8803-1ca5a54c467c"><content styleCode="bold">07-19-41-631</content></paragraph></text>
<effectiveTime value="20060531" />
</section>
</component>
</structuredBody>
</component>
</document>
